Patrick Baeuerle - 11 Feb 2022 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Acting Chief Scientific Officer, Biologics
Signature
/s/ Jeffrey Trigilio, Attorney-in-Fact
Issuer symbol
CGEM
Transactions as of
11 Feb 2022
Net transactions value
$0
Form type
4
Filing time
15 Feb 2022, 15:48:05 UTC
Previous filing
09 Sep 2021
Next filing
21 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Award $0 +37,500 $0.000000 37,500 11 Feb 2022 Direct F1
holding CGEM Common Stock 341,434 11 Feb 2022 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Award $0 +75,000 $0.000000 75,000 11 Feb 2022 Common Stock 75,000 $13.60 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the restricted stock unit vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
F2 Shares held directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
F3 The shares underlying the option vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

Remarks:

Acting Chief Scientific Officer, Biologics